PMN Stock Forecast & Price Target

ProMIS Neurosciences is compelling because PMN310 is built around a differentiated “oligomer-first” Alzheimer’s hypothesis, selectively targeting toxic amyloid-beta oligomers while sparing plaque, which could preserve efficacy while reducing the ARIA liability that limits approved antibodies. The PRECISE-AD Phase 1b study in 144 patients has strengthened that thesis with zero ARIA-E across genotypes, placebo-like ARIA-H at 4.4%, and biomarker declines of 15% in plasma pTau217 and 13.3% in CSF MTBR-tau243, suggesting real target engagement and a potentially cleaner safety profile. Financially, the company reported a 2Q26 net loss of $11.7MM, held about $53.4MM in cash, and management indicated funding is sufficient through 2027, giving it runway to reach the 1Q27 unblinded topline that could unlock substantial value.

ProMIS Neurosciences is viewed negatively because PMN310 remains in PRECISE-AD P1b with only a 20% PoS, while Alzheimer’s drug development is notoriously difficult and prior biologically plausible Aβ approaches have failed to improve cognition or slow progression. The interim biomarker readout may be hard to interpret because all cohorts are pooled to preserve blinding, potentially diluting signal, and the program faces intense competition from approved Aβ mAbs and new entrants like trontinemab if it cannot show superior safety or efficacy, especially lower ARIA. Financially, later-stage P2b/3 Alzheimer’s trials are large and costly, so ProMIS may need to raise significant capital that could be dilutive, compounding execution and commercialization risk even if approval is achieved.